Background: To evaluate the clinical outcomes of patients treated with 3D conformal Hypo-fractionated, deep Inspiratory breath-hold (DIBH), Partial breast radiotherapy, termed "HIP." HIP was implemented to merge the schedule of once-daily breast hypofractionation with partial breast treatment. Methods: We identified 38 breast cancers in 37 patients from 2013 to 2014 treated at our institution with HIP following lumpectomy for early stage breast cancer. Patients received a hypo-fractionated course (≤ 20 fractions) of once daily radiation to the partial breast (lumpectomy cavity + margin) utilizing DIBH regardless of laterality. Clinical and treatment-related characteristics were obtained, including target volume and organ at risk (OAR) dosimetric characteristics. Patients were followed clinically and with at least yearly mammograms for up to 36months (range 5-36months). Acute and late toxicity was scored using the Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Results: Patients received a median dose of 42.56Gy in 16 Fractions (Fx) (range 40.05-53.2Gy; and 15-20 Fx). OAR doses were low, with a mean heart dose of 0.37Gy, an ipsilateral lung V20 mean of 4%, and a contralateral lung V5 of 1%. Acute toxicity (≤ grade 2) was present in 79% (n=30) of the cases, with dermatitis being the most common finding (63%). Late grade 1-2 toxicity was present in 42% (n=16) of the cases, with hyperpigmentation being the most common finding (n=9). There were no severe acute or late toxicities (≥ grade 3). At a median follow up of 21months, there were no local, regional, or distant failures. Conclusions: We report limited toxicity in this low risk cohort of patients with early stage breast cancer treated with HIP, a unique and logical combination of 3-D conformal external beam radiotherapy, moderate hypo-fractionation, and DIBH.
- Acute toxicity
- Breast cancer
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging